At BioVie, our quest for innovation is driven by a deep-seated commitment to addressing some of the most pressing medical challenges of our times.
Bezisterim (NE3107)
Recent advancements in both neuroscience and biotechnology have identified neuroinflammation and insulin resistance as critical drivers of neurodegenerative disorders. At the heart of our scientific journey is bezisterim (NE3107), an oral small molecule, blood-brain barrier (BBB) permeable, anti-inflammatory insulin sensitizer that modulate the activity of extracellular signal-regulated kinase (ERK) and Nuclear Factor kappa-B (NFkB) to target and address these key pathological processes. Instead of merely alleviating symptoms, our approach aims to modify the very course of these diseases, offering hope for a brighter, more stable future for patients.
BIV-201
We are also investigating BIV-201 for the treatment of ascites. BIV-201 is a novel, continuous infusion formulation of terlipressin delivered via a small, portable pump that patients can wear while engaging in typical tasks and activities at home. We believe that BIV-201 may have the potential to slow the build-up of ascites fluid in the abdomen, and that it may do so by constricting certain blood vessels, potentially contributing to improved blood flow in the kidneys and liver.
Publications
Our groundbreaking publications delve into the promising intersection of critical health challenges, including Parkinson's disease, Alzheimer's disease, biological aging processes and ascites/cirrhosis. Through our publications, we explore our innovative approaches and outline findings that can advance our understanding and treatment of these complex and debilitating conditions.
Clinical Trials
At BioVie, our commitment to advancing healthcare through scientific innovation is demonstrated daily through our robust research and development initiatives. Central to this are our clinical trials – crucial, scientifically rigorous testing processes designed to evaluate the safety, effectiveness, and optimal usage of new medical interventions.
Additional information will be provided when we start enrolling our next trials.